The Name on the Frames: Who Owns Eye Care, and What Changes When It's Bought

Private equity has bought eye surgeons' and optometrists' practices, and one company makes many of the lenses, owns or licenses many of the frame brands, runs large optical chains and owns a vision insurer. Who the owners are, what studies found after practices were bought, what has happened to prices, where specialists are scarce, the lawsuits, California's rules, and what each side argues.

The short version

Eye care has two kinds of big owners. Private equity firms have bought ophthalmology practices, where surgeons treat cataracts, glaucoma and retina disease, and optometry offices, where most people get their exams and glasses: hundreds of purchases since 2012, most of them after 2016. Estimates of their reach run from about 5% to 17% of ophthalmologists, depending on the method and the year, but nearly 30% of retina specialists are affiliated with private equity. After purchases, studies found higher prices paid by commercial insurers, more use of an expensive retina drug, and 19.6% fewer retinal-detachment repairs, a surgery Medicare pays less for than it costs. On the other side of the counter, EssilorLuxottica makes Varilux, Crizal and Transitions lenses, owns Ray-Ban and Oakley, makes frames for Chanel and Prada, runs LensCrafters, Pearle Vision, Target Optical and Sunglass Hut, and owns the vision plan EyeMed; its main rival, VSP, owns frame makers, labs and its own chains. Meanwhile, the price index for eyeglasses and eye care has risen about half as fast as consumer prices overall since 2000. One of the largest eye care groups, EyeCare Partners, is selling its more than 300 optometry offices to pay down debt, and drug distributors have begun buying eye practices.

New articles and charts arrive in one short email on Monday mornings. Get the weekly digest

The analogy

A supermarket chain that also owns the farms, the brands on the shelves and the coupon program its customers pay with. Shoppers see a familiar store and familiar labels; the same company is on several sides of the sale.

The farms are the lens factories and frame makers, the shelf brands are Ray-Ban, Oakley and the fashion labels, the supermarket is the optical chain, and the coupon program is the vision plan. The eye doctor whose office is inside or next to the store is usually a separate business, and that business, too, may now belong to an investor.

Figures below are as of early November 2026.

How big the field is

There were 21,387 private optometrists' offices with employees in 2025, up from 20,670 in 2016, employing about 155,000 people (BLS, establishments; BLS, employees). Optometrists who work in optical stores are counted with the stores, and ophthalmologists' practices are counted with other physicians' offices. The BLS counted 45,100 optometrist jobs in 2025, with median pay of $136,570; 61% worked in optometrists' offices, 14% in physicians' offices and 13% in stores (BLS).

How much private equity owns depends on who is counting:

Where specialists are scarce

Most Americans live near an eye doctor: one study found 91% within a 30-minute drive of an ophthalmologist and 95% within 30 minutes of an optometrist (Franco and Pineda, Ophthalmology, 202400457-3/abstract)). An optometrist quoted by Review of Optometry said the study left out about a third of optometrists and ignored how long patients wait for an appointment (Review of Optometry). Counties are another matter: in 2021, 62.7% of U.S. counties had no practicing ophthalmologist outside the federal system, up from 60.7% in 2010 (Shah et al., Graefe's Archive, 2026). Subspecialists are scarcer still. A 2026 study identified about 2,500 fellowship-trained retina specialists in 2025, and found that a third of rural residents lived more than an hour's drive from one, against 1.6% of city residents (Franco et al., Retina, 2026; Review of Optometry).

Where only one or two practices have a given specialist, patients are sent there whoever owns it. Ownership then matters less for where a patient goes than for who controls the path from the first exam to the surgery and the bill, when one group owns both the general eye doctors and the specialists they refer to. The Government Accountability Office's 2025 review found that studies of private equity–owned physician practices showed higher commercial prices in some specialties, ophthalmology among them, and that the effects varied with how concentrated a market was (GAO).

The big groups

Location counts are each group's own or trade-press counts:

New buyers. Drug distributors have started buying eye practices. Cencora paid about $4.4 billion in January 2025 for about 85% of Retina Consultants of America, which the private equity firm Webster Equity Partners had formed in 2020 (Cencora, SEC filing; KFF Health News), and McKesson about $850 million in April 2025 for 80% of PRISM Vision (McKesson).

Why doctors sell

The reasons groups and their advisers give are scale and pressure. The number of ophthalmologists has been about the same since 1990, half of them are over 50, and demand from patients 65 and older is projected to grow 42% by 2030, according to the American Academy of Ophthalmology (Becker's ASC, citing the AAO). Michael Kroin, whose firm helps doctors sell practices to private equity, told KFF Health News that doctors face hospitals buying practices and insurance paperwork: "If you're not growing, it's going to be tough to survive and make a similar level of income as you had historically." The academy's president said investors can help practices with marketing and with negotiating prices for drugs and supplies (KFF Health News). Eye care also has a profitable sideline that insurance doesn't set the price of: upgrades such as laser-assisted cataract surgery and lens implants that reduce the need for glasses, which patients often pay for themselves (same source).

What eye care costs

The BLS price index for eyeglasses and eye care rose about 46% from September 2000 to September 2026, while consumer prices overall rose 94%. Since September 2019 it rose 15.4%, against 31.2% overall, and in the year to September 2026 it rose 1.1%, against 3.7% (BLS, eyeglasses and eye care; BLS, all items). That is the opposite of vet care and dental care, whose prices outran inflation. The index follows the price of comparable items and adjusts for quality, so it doesn't show whether patients are being sold costlier lenses, coatings or surgical upgrades than before, and it doesn't cover what Medicare pays for surgery.

Price change: eyeglasses and eye care and all consumer prices

Consumer price indexes, not seasonally adjusted. Source: BLS, eyeglasses and eye care; BLS, all items

What the evidence shows

The studies below compare practices private equity bought with similar practices it didn't; they show what changed after a purchase, not why.

Patients' accounts aren't evidence of a pattern, but they show what the debate is about. KFF Health News described a St. Louis patient who paid $3,000 out of pocket for an astigmatism upgrade during cataract surgery that she said didn't fix her astigmatism ("You're a cow among a herd," she said), and a Cincinnati patient, happy with his results, who said he paid more than $2,000 out of pocket per eye for laser-assisted surgery and hadn't known about the cheaper manual version, which the reporters described as just as effective. EyeCare Partners, which owns the St. Louis practice and later bought the Cincinnati one, declined to comment.

The other side of the counter

EssilorLuxottica, formed when the French lens maker Essilor merged with the Italian frame maker Luxottica in 2018, had €28.5 billion in revenue in 2025, about €12.8 billion of it in North America (Vision Monday). Its annual report lists (EssilorLuxottica, 2025 universal registration document):

It bought the streetwear brand Supreme in 2024, and Meta, its partner on Ray-Ban and Oakley smart glasses, bought just under 3% of the company in 2025 (annual report; Bloomberg Law). We found no reliable public estimate of its share of U.S. lens or frame sales.

VSP Vision, which reports more than 85 million members, calls itself the largest not-for-profit vision benefits company (VSP Vision, 2024 impact report; CalChamber), though the IRS revoked its federal tax exemption effective 2003 (20/20). It, too, sits on several sides: it owns the frame maker Marchon, the Visionworks and Eyemart Express chains and VSP Optics labs (VSP Vision), and in December 2025 it completed its purchase of the Italian frame maker Marcolin, which makes Tom Ford and Guess frames (FashionUnited). Among the independent chains, National Vision, which runs America's Best, had about 1,250 stores in 2025 (National Vision, via Business Wire), and Warby Parker 323 (Warby Parker, SEC filing).

The fights. In 2012 60 Minutes asked why glasses cost so much. In a letter to customers after the broadcast, Luxottica USA's chief executive, Andrea Dorigo, wrote that Luxottica made "only a fraction of the 150 million frames and sunglasses sold every year" and that it had "never tried to abuse" its leadership position (20/20). A 2024 class action accused EssilorLuxottica of monopolizing premium eyewear. A federal judge dismissed it in September 2025, finding that the market it described lumped together lenses, frames and sunglasses, which aren't substitutes for one another. On October 30, 2026 the U.S. Court of Appeals for the Second Circuit affirmed, finding that the plaintiffs had defined "premium" by who sold the frames rather than by price (A&O Shearman; MLex).

Contact lenses

Four makers, Johnson & Johnson, Alcon, CooperVision and Bausch + Lomb, sell about 95% of the world's contact lenses, Cooper Companies' chief executive estimated in 2018 (Cooper Companies). After the makers set minimum retail prices for some lenses in 2013 and 2014, buyers sued; the four makers and a distributor settled for a combined $118 million by 2022, and Johnson & Johnson and Alcon did so without admitting liability (settlement site; MedTech Dive). A 2003 federal law requires eye doctors to give patients their contact lens prescription so they can buy lenses elsewhere (Fairness to Contact Lens Consumers Act), and in 2020 the FTC added a rule that patients sign to confirm they got it, over optometrists' objections (Vision Monday).

The rules

California law keeps optometrists and optical sellers apart. It bars optometrists from sharing ownership or profits with optical companies or dispensing opticians, and bars dispensing opticians from employing them (Cal. Bus. & Prof. Code § 655; § 2556). Optical chains challenged the rules and lost in a federal appeals court in 2012 (National Association of Optometrists and Opticians v. Harris). A 2015 law let optometrists lease space in optical stores if they own and fully control their practice, including its fees, staff and scheduling; LensCrafters, Walmart and the state optometric association supported it, and the state Board of Optometry opposed it (California Senate analysis).

California's 2025 law limiting private equity's control of medical and dental practices took effect January 1, 2026. It bars private equity groups and hedge funds from interfering in doctors' clinical judgment, including decisions on referrals, and from controlling business matters such as coding and billing. It covers physician practices, so ophthalmology is included, but it doesn't mention optometrists (SB 351). The dental part of this series describes the law in more detail.

Where the analogy breaks

Supermarket shoppers see prices, compare stores and judge the food. Eye patients often pay through a vision plan's allowance, can't judge for themselves whether a surgical upgrade is worth it, and are often sent to a practice by another doctor or in an emergency, without knowing who owns it, as KFF Health News found.

What people argue about

Scale. Kroin argues that practices need to grow to compete with hospitals and cope with insurers, and the academy's president credited investors with helping practices market themselves, expand and negotiate prices for drugs and supplies (KFF Health News). Unifeye, for one, describes itself as physician-led. On eyewear, Luxottica said in 2012 that it had never tried to abuse its position.

Profit over care. The same academy president warned that the drive to maximize profit risks compromising care, and Aditi Sen of the Health Care Cost Institute said the firms "are not selecting practices randomly." Lawrence Casalino of Weill Cornell Medicine doubted that most practices are "so inefficient that you can get 20% more profit out of them" and warned that the model depends on reselling to a buyer who pays more (KFF Health News). Critics point to the retinal-detachment study; others point to the flat Medicare spending in another study and to eye care's slow price growth.

What's unsettled. No study has measured referral patterns inside the groups, the 2022 commercial-price study didn't publish separate ophthalmology figures in its main text, and no public data show how much of the U.S. lens and frame market EssilorLuxottica holds. And EyeCare Partners said it would use the proceeds of its optometry sale to reduce debt, so the groups' own finances are part of the story.

See also

Sources

The weekly digest

One email on Monday mornings: the week's new articles and charts, the numbers that moved most, and what comes out in the week ahead. No ads, and no tracking of opens or clicks.

Past issuesHow addresses are kept